PoplarV1, Main, Exploration, bibRecord, 001C62

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.

Identifieur interne : 001C62 ( Main/Exploration ); précédent : 001C61; suivant : 001C63

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.

Auteurs : G Paul Amminger [Australie] ; Miriam R. Sch Fer [Australie] ; Monika Schlögelhofer [Autriche] ; Claudia M. Klier [Autriche] ; Patrick D. Mcgorry [Australie]

Source :

Nature communications [ 2041-1723 ] ; 2015.

RBID : pubmed:26263244

Descripteurs français

KwdFr :
- Acides gras omega-3 (administration et posologie), Acides gras omega-3 (usage thérapeutique), Adolescent (MeSH), Adulte (MeSH), Calendrier d'administration des médicaments (MeSH), Femelle (MeSH), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Méthode en double aveugle (MeSH), Troubles psychotiques (prévention et contrôle).
MESH :
- administration et posologie : Acides gras omega-3.
- prévention et contrôle : Troubles psychotiques.
- usage thérapeutique : Acides gras omega-3.
- Adolescent, Adulte, Calendrier d'administration des médicaments, Femelle, Humains, Jeune adulte, Mâle, Méthode en double aveugle.

English descriptors

KwdEn :
- Adolescent (MeSH), Adult (MeSH), Double-Blind Method (MeSH), Drug Administration Schedule (MeSH), Fatty Acids, Omega-3 (administration & dosage), Fatty Acids, Omega-3 (therapeutic use), Female (MeSH), Humans (MeSH), Male (MeSH), Psychotic Disorders (prevention & control), Young Adult (MeSH).
MESH :
- chemical , administration & dosage : Fatty Acids, Omega-3.
- chemical , therapeutic use : Fatty Acids, Omega-3.
- prevention & control : Psychotic Disorders.
- Adolescent, Adult, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Young Adult.

Abstract

Long-chain omega-3 polyunsaturated fatty acids (PUFAs) are essential for neural development and function. As key components of brain tissue, omega-3 PUFAs play critical roles in brain development and function, and a lack of these fatty acids has been implicated in a number of mental health conditions over the lifespan, including schizophrenia. We have previously shown that a 12-week intervention with omega-3 PUFAs reduced the risk of progression to psychotic disorder in young people with subthreshold psychotic states for a 12-month period compared with placebo. We have now completed a longer-term follow-up of this randomized, double-blind, placebo-controlled trial, at a median of 6.7 years. Here we show that brief intervention with omega-3 PUFAs reduced both the risk of progression to psychotic disorder and psychiatric morbidity in general in this study. The majority of the individuals from the omega-3 group did not show severe functional impairment and no longer experienced attenuated psychotic symptoms at follow-up.

DOI: 10.1038/ncomms8934
PubMed: 26263244
PubMed Central: PMC4918317

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001B71
to stream Main, to step Curation: 001B71

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.</title>
<author><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sch Fer, Miriam R" sort="Sch Fer, Miriam R" uniqKey="Sch Fer M" first="Miriam R" last="Sch Fer">Miriam R. Sch Fer</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schlogelhofer, Monika" sort="Schlogelhofer, Monika" uniqKey="Schlogelhofer M" first="Monika" last="Schlögelhofer">Monika Schlögelhofer</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna 1090, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna 1090</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klier, Claudia M" sort="Klier, Claudia M" uniqKey="Klier C" first="Claudia M" last="Klier">Claudia M. Klier</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna 1090, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna 1090</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26263244</idno>
<idno type="pmid">26263244</idno>
<idno type="doi">10.1038/ncomms8934</idno>
<idno type="pmc">PMC4918317</idno>
<idno type="wicri:Area/Main/Corpus">001B71</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001B71</idno>
<idno type="wicri:Area/Main/Curation">001B71</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001B71</idno>
<idno type="wicri:Area/Main/Exploration">001B71</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.</title>
<author><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sch Fer, Miriam R" sort="Sch Fer, Miriam R" uniqKey="Sch Fer M" first="Miriam R" last="Sch Fer">Miriam R. Sch Fer</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schlogelhofer, Monika" sort="Schlogelhofer, Monika" uniqKey="Schlogelhofer M" first="Monika" last="Schlögelhofer">Monika Schlögelhofer</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna 1090, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna 1090</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klier, Claudia M" sort="Klier, Claudia M" uniqKey="Klier C" first="Claudia M" last="Klier">Claudia M. Klier</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna 1090, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna 1090</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature communications</title>
<idno type="eISSN">2041-1723</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Double-Blind Method (MeSH)</term>
<term>Drug Administration Schedule (MeSH)</term>
<term>Fatty Acids, Omega-3 (administration & dosage)</term>
<term>Fatty Acids, Omega-3 (therapeutic use)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Psychotic Disorders (prevention & control)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acides gras omega-3 (administration et posologie)</term>
<term>Acides gras omega-3 (usage thérapeutique)</term>
<term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Calendrier d'administration des médicaments (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Méthode en double aveugle (MeSH)</term>
<term>Troubles psychotiques (prévention et contrôle)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Fatty Acids, Omega-3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Fatty Acids, Omega-3</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acides gras omega-3</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Troubles psychotiques</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acides gras omega-3</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Calendrier d'administration des médicaments</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Long-chain omega-3 polyunsaturated fatty acids (PUFAs) are essential for neural development and function. As key components of brain tissue, omega-3 PUFAs play critical roles in brain development and function, and a lack of these fatty acids has been implicated in a number of mental health conditions over the lifespan, including schizophrenia. We have previously shown that a 12-week intervention with omega-3 PUFAs reduced the risk of progression to psychotic disorder in young people with subthreshold psychotic states for a 12-month period compared with placebo. We have now completed a longer-term follow-up of this randomized, double-blind, placebo-controlled trial, at a median of 6.7 years. Here we show that brief intervention with omega-3 PUFAs reduced both the risk of progression to psychotic disorder and psychiatric morbidity in general in this study. The majority of the individuals from the omega-3 group did not show severe functional impairment and no longer experienced attenuated psychotic symptoms at follow-up. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26263244</PMID>
<DateCompleted><Year>2016</Year>
<Month>04</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>04</Month>
<Day>26</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>6</Volume>
<PubDate><Year>2015</Year>
<Month>Aug</Month>
<Day>11</Day>
</PubDate>
</JournalIssue>
<Title>Nature communications</Title>
<ISOAbbreviation>Nat Commun</ISOAbbreviation>
</Journal>
<ArticleTitle>Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.</ArticleTitle>
<Pagination><MedlinePgn>7934</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms8934</ELocationID>
<Abstract><AbstractText>Long-chain omega-3 polyunsaturated fatty acids (PUFAs) are essential for neural development and function. As key components of brain tissue, omega-3 PUFAs play critical roles in brain development and function, and a lack of these fatty acids has been implicated in a number of mental health conditions over the lifespan, including schizophrenia. We have previously shown that a 12-week intervention with omega-3 PUFAs reduced the risk of progression to psychotic disorder in young people with subthreshold psychotic states for a 12-month period compared with placebo. We have now completed a longer-term follow-up of this randomized, double-blind, placebo-controlled trial, at a median of 6.7 years. Here we show that brief intervention with omega-3 PUFAs reduced both the risk of progression to psychotic disorder and psychiatric morbidity in general in this study. The majority of the individuals from the omega-3 group did not show severe functional impairment and no longer experienced attenuated psychotic symptoms at follow-up. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amminger</LastName>
<ForeName>G Paul</ForeName>
<Initials>GP</Initials>
<AffiliationInfo><Affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schäfer</LastName>
<ForeName>Miriam R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Schlögelhofer</LastName>
<ForeName>Monika</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna 1090, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Klier</LastName>
<ForeName>Claudia M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna 1090, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McGorry</LastName>
<ForeName>Patrick D</ForeName>
<Initials>PD</Initials>
<AffiliationInfo><Affiliation>Orygen-The National Centre of Excellence in Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>08</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Nat Commun</MedlineTA>
<NlmUniqueID>101528555</NlmUniqueID>
<ISSNLinking>2041-1723</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>11</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>06</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>8</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>8</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26263244</ArticleId>
<ArticleId IdType="pii">ncomms8934</ArticleId>
<ArticleId IdType="doi">10.1038/ncomms8934</ArticleId>
<ArticleId IdType="pmc">PMC4918317</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2010 Feb;67(2):146-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20124114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Psychiatry. 2011 Dec;168(12 ):1311-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21768612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Psychiatry. 2006 Dec;67(12):1954-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17194275</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Schizophr Res. 2004 Apr 1;67(2-3):131-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14984872</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Gen Psychiatry. 2002 Oct;59(10):921-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12365879</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biol Psychiatry. 2014 Jan 1;75(1):38-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23890734</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuropsychiatr. 2007;21(1):37-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17555006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Schizophr Bull. 1996;22(2):271-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8782286</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Schizophr Bull. 1996;22(2):283-303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8782287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Neurosci. 2005 Nov;6(11):877-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16261181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuron. 2014 Sep 3;83(5):1073-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25132466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Gen Psychiatry. 2012 Mar;69(3):220-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22393215</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2010 Nov 11;468(7321):187-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21068826</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Psychiatry. 2012 Mar;25(2):83-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22249081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Psychiatry Suppl. 1998;172(33):14-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9764121</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Psychiatry Res. 2013 May 15;207(1-2):1-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23068078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2012;18(4):576-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22239591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Psychiatry. 2011 Aug;168(8):800-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21498462</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Schizophr Res. 2013 Sep;149(1-3):56-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23870806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Gen Psychiatry. 2005 Sep;62(9):975-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16143729</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Psychiatry. 2004 Oct;185:291-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15458988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Jan 25;361(9354):281-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12559861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Psychiatry. 2013 Aug;70(8):793-802</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23739772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Psychiatry. 2015 Mar 1;172(3):249-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25727537</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>Autriche</li>
</country>
<region><li>Victoria (État)</li>
<li>Vienne (Autriche)</li>
</region>
<settlement><li>Melbourne</li>
<li>Vienne (Autriche)</li>
</settlement>
<orgName><li>Université de Melbourne</li>
</orgName>
</list>
<tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name>
</region>
<name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name>
<name sortKey="Sch Fer, Miriam R" sort="Sch Fer, Miriam R" uniqKey="Sch Fer M" first="Miriam R" last="Sch Fer">Miriam R. Sch Fer</name>
</country>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Schlogelhofer, Monika" sort="Schlogelhofer, Monika" uniqKey="Schlogelhofer M" first="Monika" last="Schlögelhofer">Monika Schlögelhofer</name>
</region>
<name sortKey="Klier, Claudia M" sort="Klier, Claudia M" uniqKey="Klier C" first="Claudia M" last="Klier">Claudia M. Klier</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C62 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C62 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    PoplarV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:26263244
   |texte=   Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:26263244" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PoplarV1

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 12:07:19 2020. Site generation: Wed Nov 18 12:16:31 2020

	Serveur d'exploration sur le peuplier
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le peuplier

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki